Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

JOHNSON & JOHNSON

(JNJ)
  Report
Delayed Nyse  -  04:00 2022-11-29 pm EST
176.09 USD   -0.70%
04:56pHorizon Therapeutics Confirms 'Highly Preliminary Discussions' With Three Suitors -- Shares Halted After-Hours
MT
11/28LIDDS AB (publ) Interim Report January – September 2022
AQ
11/23Sector Update: Health Care Stocks Advancing Wednesday Afternoon
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
Days
:
Hours
:
Minutes
:
Seconds

Johnson & Johnson : davis, ian

02/15/2018 | 06:21pm EST

FORM 4

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5


1. Name and Address of Reporting Person * Davis Ian 2. Issuer Name and Ticker or Trading Symbol JOHNSON & JOHNSON [ JNJ ] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) __ X __ Director _____ 10% Owner
_____ Officer (give title below) _____ Other (specify below)
ONE JOHNSON & JOHNSON PLAZA 3. Date of Earliest Transaction (MM/DD/YYYY)
NEW BRUNSWICK, NJ 08933 4. If Amendment, Date Original Filed (MM/DD/YYYY) 6. Individual or Joint/Group Filing (Check Applicable Line) _ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Deferred Share Units (1) 2/13/2018 A 1428.0000 (1) (1) Common Stock 1428.0000 $0.0000 11304.1160 D

Explanation of Responses:
(1) Grant of Deferred Share Units acquired under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each Deferred Share Unit representing the fair market value of one share of Common Stock on the settlement date).

Reporting Owners
Reporting Owner Name / Address
Director 10% Owner Officer Other
Davis Ian
ONE JOHNSON & JOHNSON PLAZA
NEW BRUNSWICK, NJ 08933
X

Signatures
Linda E. King, as attorney-in-fact for Ian Davis 2/15/2018
** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Johnson & Johnson published this content on 15 February 2018 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 15 February 2018 23:20:01 UTC.


ę Publicnow 2018
All news about JOHNSON & JOHNSON
04:56pHorizon Therapeutics Confirms 'Highly Preliminary Discussions' With Three Suitors -- Sh..
MT
11/28LIDDS AB (publ) Interim Report January – September 2022
AQ
11/23Sector Update: Health Care Stocks Advancing Wednesday Afternoon
MT
11/23Sector Update: Health Care Stocks Still Advancing in Wednesday Trading
MT
11/23Sector Update: Health Care
MT
11/23Correction: Fed Minutes Eyed for Signs of Slower Fed Rate Hikes as ETFs, Stoc..
MT
11/23Fed Minutes Eyed for Signs of Slower Fed Rate Hikes as ETFs, Stock Futures Inch Higher ..
MT
11/23Johnson & Johnson's Janssen Pharmaceutical Says Phase 3 Trial of Major Depressive Disor..
MT
11/21Insider Sell: Johnson & Johnson
MT
11/21JOHNSON & JOHNSON : Ex-dividend day for
FA
More news
Analyst Recommendations on JOHNSON & JOHNSON
More recommendations
Financials (USD)
Sales 2022 95 043 M - -
Net income 2022 20 677 M - -
Net cash 2022 11 030 M - -
P/E ratio 2022 22,2x
Yield 2022 2,48%
Capitalization 460 B 460 B -
EV / Sales 2022 4,73x
EV / Sales 2023 4,52x
Nbr of Employees 141 700
Free-Float 83,8%
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Last Close Price 176,09 $
Average target price 181,36 $
Spread / Average Target 2,99%
EPS Revisions
Managers and Directors
Joaquin Duato Chief Executive Officer & Director
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Matthew Stuckley Senior Financial Analyst-Janssen Commercial Pharm
Alex Gorsky Executive Chairman
Peter Shen Global Head-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
JOHNSON & JOHNSON3.66%463 626
ELI LILLY AND COMPANY32.23%347 547
ABBVIE INC.17.01%280 085
PFIZER, INC.-16.05%278 252
MERCK & CO., INC.41.51%274 964
ROCHE HOLDING AG-17.59%271 275